News & Updates
Filter by Specialty:
Two-drug combo rises to the challenge as 1L Tx for mTNBC
02 Jul 2025
byAudrey Abella
In the primary analysis of the ASCENT-04/KEYNOTE-D19 study, a combination regimen comprising sacituzumab govitecan (SG) and pembrolizumab delivers significant progression-free survival (PFS) benefit in women with previously untreated PD-L1+ advanced triple-negative breast cancer (TNBC).
Two-drug combo rises to the challenge as 1L Tx for mTNBC
02 Jul 2025
Dienogest in long-term management of endometriosis
24 Jun 2025
byDr. Yong-Wook Jung, Cha Gangnam Medical Center, South Korea; Dr. Pong-Mo Yuen, Director of Minimally Invasive Gynaecology, Hong Kong Sanatorium & Hospital
Characterized by high postpartum and postoperative recurrence rates, endometriosis requires continuous management. At a Bayer-sponsored symposium, Dr Yong-Wook Jung of Cha Gangnam Medical Center, South Korea, discussed the paradigm shift in the management of endometriosis, while Dr Pong-Mo Yuen, Director of Minimally Invasive Gynaecology at Hong Kong Sanatorium & Hospital, shared several patient cases illustrating long-term treatment with dienogest.
